On 5 September, the VUmc team recruited its 100th participant in the AMYPAD Diagnostic and Patient Management study (DPMS), an accomplishment resulting from researchers, clinicians and research participants coming together to support research for Alzheimer’s disease.
The VUmc centre is one of the eight European participating sites. We now have more than 450 out of 900 subjects enrolled since the study was initiated last April 2018. The DPMS has reached the 50% recruitment mark and we are very happy to be at this point now. The team is proud and confident of the timely impact this study will have on the field.
In this clinical study, researchers aim to include subjects suspected of possible Alzheimer’s disease and determine the usefulness of β-amyloid imaging as a diagnostic marker for Alzheimer’s disease. The study involves people with dementia, but also subjects with mild cognitive impairment (MCI) or subjective cognitive decline (SCD), and investigates the impact of β-amyloid PET on both diagnostic confidence, patient management and resource utilisation.